Alterations in CMA activity directly impact α-synuclein levels, with the loss of CMA activity linked to α-synuclein accumulation in numerous in vitro and in vivo PD models, as well as in samples derived from PD patients [64,65,66]. Here, SNCA is linked to Parkinson disease.